Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Aurinia Pharmaceuticals Inc. (AUPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $11.01 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.94, a 50.48% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $7.27, a 37.44% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.62, a 19.47% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $14.43, a 11.31% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $12.18, a 3.64% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $12.64, a 21.39% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $16.08, a 99.89% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $14320.00, a 3.47% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.01 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $10.94 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $12.18 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $12.12 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | $12.22 10-Q · filed 2025-07-31 | ||||
| 2025-03-31 | $7.27 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $12.64 10-K · filed 2025-02-27 | ||||
| 2024-09-30 | $12.81 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $12.47 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $11.62 10-Q · filed 2024-05-02 | ||||
| 2023-12-31 | $16.08 10-K · filed 2024-02-15 | ||||
| 2023-09-30 | $14.11 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $14.58 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $14.43 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $14320.00 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $14.63 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $15.73 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $16.27 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $13840.00 10-K · filed 2022-02-28 | ||||
| 2020-12-31 | $11.82 10-K · filed 2022-02-28 | $11820.00 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $5.40 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |